Sugi Predict

Sugi Predict / Compounds / SCHEMBL956911

SCHEMBL956911

SCHEMBL956911

O=C(/C=C/C(=O)Oc1ccc([N+](=O)[O-])cc1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.61
▸ BCL9 O00512 1/20 0.57
▸ CTNNB1 P35222 1/20 0.57
▸ KMT2A Q03164 4/20 0.56
▸ PKM P14618 1/20 0.56
▸ CES1 P23141 2/20 0.52
▸ CA1 P00915 1/20 0.52
▸ CA2 P00918 1/20 0.52
▸ CES2 O00748 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ MAPT P10636 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ MGLL Q99685 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ MYOC Q99972 1/20 0.50
▸ MAOA P21397 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4661270 1.00 GAA (0.61) GAABCL9CTNNB1KMT2APKM
SCHEMBL4296577 0.93 GAA (0.54) GAABCL9CTNNB1KMT2APKM
SCHEMBL2108301 0.93 GAA (0.54) GAABCL9CTNNB1KMT2APKM
SCHEMBL17695797 0.91 GAA (0.57) GAABCL9CTNNB1KMT2APKM
Ammonia Solution, Strong SCHEMBL9436297 0.91 GAA (0.53) GAABCL9CTNNB1KMT2APKM
Ammonia Solution, Strong SCHEMBL9436280 0.91 GAA (0.53) GAABCL9CTNNB1KMT2APKM
SCHEMBL9359869 0.91 GAA (0.53) GAABCL9CTNNB1KMT2APKM
SCHEMBL12858124 0.91 ACHE (0.60) GAABCL9CTNNB1KMT2APKM
SCHEMBL6831012 0.89 GAA (0.54) GAABCL9CTNNB1KMT2APKM
SCHEMBL11973529 0.89 GAA (0.58) GAABCL9CTNNB1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110008441-A1 THERMORESPONSIVE ARGININE-BASED HYDROGELS AS BIOLOGIC CARRIERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-01-13 — — US claimed
EP-2222754-A2 THERMORESPONSIVE ARGININE-BASED HYDROGELS AS BIOLOGIC CARRIERS Cornell University (US) 2010-09-01 — — EP claimed
WO-2009073541-A2 THERMORESPONSIVE ARGININE-BASED HYDROGELS AS BIOLOGIC CARRIERS CORNELL UNIVERSITY (US) 2009-06-11 — — WO claimed
EP-2222754-B1 THERMORESPONSIVE ARGININE-BASED HYDROGELS AS BIOLOGIC CARRIERS UNIV CORNELL (US) 2018-01-10 — — EP disclosed
US-9517203-B2 Polymer particle delivery compositions and methods of use MEDIV AS, LLC (US) 2016-12-13 — — US disclosed
US-9102830-B2 Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use MEDIVAS, LLC (US) 2015-08-11 — — US disclosed
US-8858998-B2 Thermoresponsive arginine-based hydrogels as biologic carriers CORNELL UNIVERSITY (US) 2014-10-14 — — US disclosed
US-8652504-B2 Solid polymer delivery compositions and methods for use thereof MEDIVAS, LLC (US) 2014-02-18 — — US disclosed
US-20130210931-A1 BIS-(ALPHA-AMINO)-DIOL-DIESTER-CONTAINING POLY (ESTER AMIDE) AND POLY (ESTER URETHANE) COMPOSITIONS AND METHODS OF USE MEDIVAS, LLC (US) 2013-08-15 — — US disclosed
EP-1926780-B1 BIS-( -AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE MEDIVAS LLC (US) 2013-08-14 — — EP disclosed
US-8445627-B2 Alkylene-dicarboxylate-containing biodegradable poly(ester-amides) and methods of use MEDIVAS, LLC (US) 2013-05-21 — — US disclosed
WO-2005121250-A2 UNSATURATED POLY(ESTER-AMIDE) BIOMATERIALS CORNELL RESEARCH FOUNDATION, INC. (US) 2005-12-22 — — WO disclosed
WO-2005112587-A2 WOUND HEALING POLYMER COMPOSITIONS AND METHODS FOR USE THEREOF MEDIVAS, LLC (US) 2005-12-01 — — WO disclosed
US-20050238689-A1 Bioactive stents for type II diabetics and methods for use thereof MEDIVAS, LLC (US) 2005-10-27 — — US disclosed
WO-2005097186-A2 BIOACTIVE STENTS FOR TYPE II DIABETICS AND METHODS FOR USE THEREOF MEDIVAS, LLC (US) 2005-10-20 — — WO disclosed
EP-1456226-A1 SITE SELECTIVE ACYLATION ModPro AB (SE) 2004-09-15 — — EP disclosed
WO-2003044042-A9 SITE SELECTIVE ACYLATION MODPRO AB (SE) 2004-04-22 — — WO disclosed
WO-2003044042-A1 SITE SELECTIVE ACYLATION MODPRO AB (SE) 2003-05-30 — — WO disclosed
EP-0952980-A1 ACYL TRANSFER WITH STABILISED TRANSITION COMPLEX USING CATALYST WITH CATALYTIC IMIDAZOLE (E.G. HISTIDINE) FUNCTION A+Science Invest AB (SE) 1999-11-03 — — EP disclosed
WO-1997043302-A1 ACYL TRANSFER WITH STABILISED TRANSITION COMPLEX USING CATALYST WITH CATALYTIC IMIDAZOLE (E.G. HISTIDINE) FUNCTION A+SCIENCE INVEST AB (SE) 1997-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050238689-A1 Bioactive stents for type II diabetics and methods for use thereof CD47, ITGB2, ITGA2 GAA 1741/4885BCL9 1600/4885CTNNB1 632/4885
US-20110008441-A1 THERMORESPONSIVE ARGININE-BASED HYDROGELS AS BIOLOGIC CARRIERS PARG, PNISR, PUF60 GAA 1903/4885BCL9 1731/4885CTNNB1 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.